Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AP4F | ISIN: CA7615161030 | Ticker-Symbol: 31R
München
05.06.25 | 08:03
0,008 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REVIVE THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
REVIVE THERAPEUTICS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,0110,03005.06.

Aktuelle News zur REVIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiRevive Therapeutics Ltd: Revive develops new bucillamine formulation3
MiRevive Therapeutics Ltd.: Revive Therapeutics Advances with Next-Generation Bucillamine Development10
13.05.Revive Therapeutics Ltd: Revive's bucillamine research study to end by June8
REVIVE THERAPEUTICS Aktie jetzt für 0€ handeln
12.05.Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure129TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
21.04.Revive Therapeutics Ltd: Revive Therapeutics to settle $150,000 debt with shares7
21.04.Revive Therapeutics announces proposed shares for debt transaction3
21.04.Revive Therapeutics Ltd.: Revive Therapeutics Announces Proposed Shares for Debt Transaction5
10.04.Revive Therapeutics Ltd: Revive to study bucillamine as cancer treatment6
10.04.Revive Therapeutics Ltd.: Revive Therapeutics to Investigate Bucillamine's Potential in Cancer Treatment206TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
01.04.Revive Therapeutics Ltd: Revive agrees to buy Diagnamed's molecular hydrogen IP7
01.04.Revive Therapeutics Ltd.: Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program228TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
19.03.Revive Therapeutics Ltd: Revive shareholders approve all matters at AGSM1
19.03.Revive Therapeutics Ltd.: Revive Therapeutics Announces Results of Annual Shareholder Meeting736TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
04.03.Revive Therapeutics Ltd: Revive to buy molecular hydrogen rights from Diagnamed2
03.02.Revive Therapeutics Ltd.: Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures266TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
08.01.Revive Therapeutics Ltd: Revive Therapeutics talks bucillamine research study5
08.01.Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure321TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
28.08.24Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections448TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
02.07.24Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure331TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
12.06.24Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID304TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1